Emergence and genetic characteristics of pyrazinamide resistant tuberculosis in China, a multi-center study by Li, D et al.
 Title page: 1 
Emergence and genetic characteristics of pyrazinamide resistant 2 
tuberculosis in China, a multi-center study 3 
 4 
Dange Li1, Yi Hu1,*, Jim Werngren3, Mikael Mansjö3, Xubin Zheng1, Francis 5 
Drobniewski4, Sven Hoffner2,3, Biao Xu1 6 
 7 
1 Department of Epidemiology, School of Public Health, Fudan University, Shanghai 8 
200032, China and Key Laboratory of Public Health Safety (Fudan University), 9 
Ministry of Education, China; 10 
2 Department of Microbiology, Cell and Tumor Biology, Karolinska Institutet, 11 
Stockholm, Sweden; 12 
3 Department of Microbiology, the Public Health Agency of Sweden, Solna, Sweden; 13 
4 Department of Infectious Diseases, Imperial College, London, UK. 14 
*Correspondence author 15 
Yi Hu, Ph.D, MPH, School of Public Health, Fudan University, 138 Yi Xue Yuan Rd., 16 
Shanghai, China, 200032;Tel.: +86 21 54237677, Fax: +86 21 54237677,  17 
E-mail addresses: yhu@fudan.edu.cn 18 
 19 
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 ABSTRACT 21 
Background: The aim of this study was to investigate the rates of pyrazinamide (PZA) 22 
resistance and the associated risk factors as well as to evaluate the pncA gene loci as a 23 
marker for PZA resistance in China. 24 
Method: A population-based multi-center study of pulmonary TB cases was carried out 25 
from 2011 to 2013 in four Chinese district/counties with different geographic and 26 
socio-economic features. Testing for multidrug-resistant tuberculosis (MDR-TB) and 27 
susceptibility to PZA were determined by the proportion method on Löwenstein-Jensen 28 
medium and BACTEC MGIT 960 respectively. Mutations in the pncA gene were 29 
identified by sequencing. 30 
Results: Among 878 culture positive cases, 147(16.7%) were resistant to PZA, with a 31 
significantly higher proportion among MDR isolates compared to the drug sensitive 32 
isolates (30.2% VS 7.7%, p<0.001). Totally, 136 isolates had a non-synonymous pncA 33 
mutation, with a comparable diagnostic performance between Beijing family and 34 
non-Beijing family as well as between MDR-TB and 1st-line drug susceptible TB. 35 
Furthermore, the mutations in isolates with high-level PZA resistance (MIC>500mg/L) 36 
were observed mainly in three regions of the pncA gene (codon 51-76, codon 130-142 37 
and codon 163-180). Patients with prior treatment history had a significantly higher 38 
risk for PZA mono-resistance (OR:2.86,95%CI:1.363-6.015) and MDR PZA resistance 39 
(OR:6.47, 95%CI:3.186-13.15), while the additional factors associated with MDR-PZA 40 
resistance were the patient’s age (OR:1.02, 95%CI:1.003-1.042), lung cavity (OR:2.64, 41 
95%CI:1.296-5.391). 42 
 Conclusions: These findings suggest that it is a priority to identify PZA resistance in 43 
MDR-TB and a rapid molecular diagnostic test based on pncA mutations in the 44 
Chinese settings where MDR-TB prevalence is high should be developed. 45 
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 Text 50 
BACKGROUND 51 
Drug-resistant M. tuberculosis (Mtb), which predominantly arises from the selection of 52 
naturally resistant bacterial strains through pressure from inappropriate chemotherapy, 53 
poses a serious challenge to global TB control (1). Because of its high bactericidal 54 
effect in an acidic environment, pyrazinamide (PZA) is usually recommended for the 55 
treatment of PZA susceptible MDR-TB throughout the entire duration of the regimen 56 
(2). An increasing number of PZA resistant (R) strains has however been observed (1) 57 
and without precise knowledge of PZA susceptibility, its unstandardized utilization in 58 
treatment regimen could lead to resistance against other antibiotics as well (particularly 59 
against efficient oral drugs, such as fluoroquinolones (FQ), that are initially included in 60 
the regimen). The unavailability of low cost drug susceptibility testing (DST) 61 
techniques, in addition to safety considerations related to the handling of MDR-TB 62 
strains, further inhibits our understanding of the scale of PZA resistance in 63 
resource-limited areas. 64 
 65 
PZA is a pro-drug that needs to be converted to an active form, pyrazinoic acid, by the 66 
bacterial pyrazinamidase (PZase) enzyme which is encoded by pncA. 67 
mutations/variations in pncA leading to the loss of PZase activity is the major 68 
mechanism leading to PZA-resistance (PZA-R)(3). However, while high numbers of 69 
PZA-R cases can be related to inactivation of the PZase, the genetic variants, including 70 
 single nucleotide polymorphisms (SNPs) and small deletions, are highly diverse and 71 
scattered over the full length of the 561 bp pncA gene(4, 5). This complicates the 72 
development of molecular tests, as no “hot spot region” comprising the majority of 73 
mutations is observed in the pncA gene. Therefore, an in-depth knowledge of the 74 
variants found in PZA-R strains combined with evidence-based correlation with 75 
resistance phenotypes are needed to develop large-scale databases ensuring valid data 76 
interpretation especially in specific local settings. 77 
 78 
China has one of the highest rates of notified cases of Mycobacterium tuberculosis. In 79 
2012, the Chinese Health Authorities reported a tuberculosis (TB) incidence of 39.5 80 
cases per 100,000 people nationwide and that 2.3% of primary TB cases were 81 
multidrug resistant (MDR-TB) cases(6). According to the National Laboratory 82 
Surveillance System for Resistance in TB, 4,170 isolates from notified cases were 83 
identified to be resistant to both isoniazid and rifampin. Despite the high burden of 84 
MDR-TB, the magnitude of PZA resistance is largely unknown in China. Since PZA is 85 
likely to remain a central component in the treatment of tuberculosis, it is critically 86 
important to understand the epidemiology of PZA resistance as well as its associated 87 
socio-demographic and clinical factors. The present study aims to fill this gap by 88 
reporting the rates of PZA resistance in newly treated patients and previously treated 89 
patients as well as the factors associated with PZA resistance in a population-based 90 
multi-center study of tuberculosis in China. 91 
 92 
 MATERIALS AND METHODS 93 
Settings 94 
Four counties from Zhejiang, Jiangsu and Sichuan provinces were selected as study 95 
sites. The population of these regions ranged from 490,000 to 3,260,000. The incidence 96 
rate of TB cases ranged from 38.2/100,000 to 78.8/100,000 and the case mortality rate 97 
ranged from 0.29% to 0.31% in 2011. The Directly Observed Treatment, Short-course 98 
(DOTS) strategy has been implemented since the early 1990s in all the study sites. All 99 
study sites were designated TB health facilities for TB diagnosis, treatment and 100 
management. As recommended by the DOTS strategy, a standardized treatment 101 
regimen is routinely applied for drug sensitive TB cases.  102 
Study design 103 
A population-based, STROBE-ME (STrengthening Reporting of OBservational studies 104 
in Epidemiology-Molecular Epidemiology)-compliant cross-sectional study was 105 
conducted from January 2011 to December 2013. Patients were enrolled if they were: 1) 106 
diagnosed as pulmonary tuberculosis patients at the local TB designated health 107 
facilities during the study period; 2) aged above 18 years old; 3) had TB culture 108 
positive sputum; 4) gave written consent for their clinical data and specimens to be 109 
used for further research. The sputum was collected in a sterile screw-top plastic 110 
container and sent to the local TB dispensaries for microbiological culture and then 111 
sent to the up-level prefectural TB laboratory for drug susceptibility testing of the 112 
 first-line drugs including PZA. The isolates were cultivated on Löwenstein-Jensen 113 
medium (L-J medium) and forwarded to the School of Public Health, Fudan University 114 
for the molecular analysis. Data regarding demographic characteristics (age, gender 115 
and geographic origin of the patient), smear microscopy were obtained by 116 
questionnaire interviews and reviews of the medical records. The patients’ 117 
identification information was replaced by a unique code in data input and analysis. 118 
The questionnaires, informed consent forms and study protocols were approved by the 119 
ethics committee of the School of Public Health, Fudan University. 120 
Identification of strains and drug susceptibility testing 121 
Identification of the Mtb isolates was performed using standard microbiological tests 122 
(niacin accumulation test and nitrate reduction test). Susceptibility to first-line 123 
anti-tuberculosis drugs including isoniazid(INH), rifampicin(RIF), ethambutol(EMB) 124 
and streptomycin (STR), were tested using the proportion method on L-J medium (INH, 125 
0.2 mg/L; RIF, 40.0 mg/L; EMB, 2.0mg/L;STR, 4.0mg/L) according to the standard 126 
procedure recommended by World Health Organization (WHO) guidelines (7, 8). The 127 
strains were examined for their susceptibility to 100 mg/L of PZA using a MGIT 128 
PZA(Nippon Becton-Dickinson Co., Ltd., Tokyo, Japan) antimicrobial susceptibility 129 
testing assay, as previously described (9). For quality assurance, the DST was repeated 130 
for 10% of the isolates by an external technician from Shanghai municipal CDC who 131 
had passed the WHO’s external quality control assurance with a consistency of over 132 
95%. No discrepancies were recorded. MDR was defined as resistance to at least 133 
 isoniazid and rifampicin. Other drug resistance (ODR) was defined as resistance to at 134 
least one of the four first-line anti-TB drugs (INH, RIF, EMB, STR) except MDR. 135 
New cases were defined as cases with no more than one-month history of anti-TB 136 
treatment. Previously treated cases were defined as cases with more than one-month 137 
history of anti-TB treatment. (10) 138 
MIC testing of PZA resistant isolates 139 
Furthermore, MIC tests for PZA resistant isolates were performed using the 140 
Mycobacterial Growth Indicator Tube (MGIT) 960 platform according to the 141 
manufacturer’s standard protocol (11). Briefly, bacterial suspensions were transferred 142 
to MGIT tubes containing serial PZA dilutions ranging from 64–1024 mg/L for PZA. 143 
Control tubes without any antibiotics were inoculated with undiluted and 1:10 diluted 144 
bacterial suspensions. The MIC was defined as the first antibiotic concentration that 145 
showed less growth than the 1:10 diluted control of the corresponding strain, i.e. the 146 
lowest concentration of the drug that inhibited more than 90% of the bacterial 147 
population. Duplicates of the Mtb H37Rv reference strain were included in each run as 148 
an inter- and intra-replication quality control. A MIC value of more than 500 mg/L was 149 
defined as high level resistance to PZA (4, 12). 150 
Molecular Characterization of PZA resistance 151 
According to Jureen et al.(13), the 561bp pncA gene, along with additional regions of 152 
approximately 200 bp up- and downstream of the gene, was sequenced using the 153 
 pncA_F3 (AAGGCCGCGATGACACCTCT) and pncA_R4 (GTGTCGTAGAAGCG 154 
GCCGAT) primers. These primers were used in a standard PCR to give a template for 155 
the subsequent sequencing reactions. The pncA_F3 and pncA_R4 primers, as well as 156 
the P3-F (ATCAGCGACTACCTGGCCGA) and P4-R 157 
(GATTGCCGACGTGTCCAGAC) primers, were used to subdivide the PCR fragment 158 
into two overlapping bidirectional sequencing reaction fragments. The sequencing 159 
reactions were performed using a BigDye Terminator cycle sequencing kit and were 160 
later run on a 3100 genetic analyzer (Applied Biosystems, Inc., Foster City, CA). 161 
Retrieved sequences were analyzed with the (ClustalW) vector NTI Advance (version 162 
9) software (InfoMax, Inc.) using the wild-typeH37Rv strain’s pncA gene (Rv2043c) 163 
as the master reference. 164 
Family strain determination 165 
Spoligotyping was performed by using commercial kits from Isogen Bioscience BV 166 
(Maarssen, The Netherlands). Comparison of spoligotyping patterns with the SpolDB4 167 
database, identified Mtb isolates belonging to the Beijing family, i.e. defined as strains 168 
that only hybridized to the last nine spacer oligonucleotides (spacers 35 to 43) (14).  169 
Statistical analysis 170 
Sensitivity was defined by the proportion of PZA resistant isolates harboring a 171 
non-synonymous pncA mutation, while the specificity was determined by the 172 
proportion of PZA susceptible isolates harboring a wild type pncA gene. An 173 
 uncorrected Chi square test or Fisher exact test was used to compare the distributions 174 
of low-level and high-level MIC among mutations in different pncA regions. The area 175 
under the receiver operating characteristic curve (ROC-AUC) was calculated to assess 176 
the performance of pncA mutations in predicting PZA resistance, yielding values from 177 
0.5 (no predictive power) to 1.0 (perfect prediction). Sensitivity, specificity and 178 
ROC-AUC were calculated by OPENEPI 179 
(http://www.openepi.com/DiagnosticTest/DiagnosticTest.htm). Statistical analysis of 180 
risk factors were performed using SPSS software (version19.0). P≤ 0.05 was 181 
considered statistically significant. Association between studied variables and PZA 182 
resistance were calculated using odds ratios (ORs) with 95% confidence intervals (CIs) 183 
respectively by univariate and multivariate analysis in a Binary Logistic Regression 184 
model. 185 
RESULTS 186 
Demographic and clinical characteristics of patients 187 
From 2011 to 2013, a total of 912 pulmonary TB patients were diagnosed and 188 
registered at the local TB dispensaries in the 4 study sites. Of the 912 sputum samples 189 
collected from these patients, 878 (96.3%) were included in the present study, while 190 
34(3.7%) were excluded due to culture-negativity or lack of drug resistance profiles for 191 
the first-line anti-TB drugs. Among the included 878 patients, 608(69.2%) were male, 192 
with an average age of 47(47.3±19.2) years. Additionally, 185(21.1%) had a prior 193 
treatment history and 227(25.9%) had cavities present in their lungs. There were no 194 
 statistically significant differences between the subjects from the four counties in terms 195 
of demographic (gender and age) or clinical characteristics (prior treatment history, 196 
sputum smear positive and cavity). (Table 1) 197 
Drug susceptibility profile 198 
In total, 400 (45.6%) isolates were resistant to at least one of the four first-line anti-TB 199 
drugs with 129 (14.7%) being simultaneously resistant to INH and RIF (MDR). Using 200 
the MGIT 960 system, PZA resistance was observed in 147(16.7%) of the 878 isolates, 201 
and ranged from 16.0% to 17.3% in the four studied sites. By comparison, the MDR 202 
isolates showed a significantly higher proportion of PZA resistance rates compared to 203 
the drug sensitive isolates (30.2%.vs.7.7%, p<0.001), while higher PZA resistance 204 
were also observed in other drug resistant isolates compared to the drug sensitive 205 
isolates (26.2% vs.7.7%, p<0.001).  206 
Molecular characterization of pncA gene 207 
Sequencing of the pncA gene revealed that 136(136/878, 15.5%) isolates harbored 208 
sequence alternations including 133 non-synonymous substitutions and 3 large 209 
fragment insertions or deletions. Additionally, one isolate carried a synonymous 210 
mutation (Ala36Ala). All substitutions occurred between nucleotide-11 and codon 180. 211 
Distribution of the substitutions are shown in Figure 1. Nucleotide-11, located in the 212 
putative promoter region, harbored the most frequent substitutions (9/133, 6.8%) while 213 
codon 57 and codon 94 had the second most frequent mutation (7/133, 5.3%). Overall, 214 
 the distributions of mutations were quite comparable between isolates with PZA 215 
mono-resistance and PZA resistance with MDR. (Figure 1) 216 
 217 
In order to investigate the role of specific pncA mutations in PZA resistance, MICs 218 
were determined for each pncA substitution (Figure 2). For the 133 isolates with 219 
non-synonymous substitutions in pncA, 72.9% (97/133) had a high-level MIC 220 
(>500mg/L) (Supplementary Table S1). Different MICs were seen for the same amino 221 
acid change in the 7 typical substitutions including promoter (A-11G), Trp68Cys, 222 
Thr76Pro, Phe94Leu, Val130Ala, Thr135Pro and Val163Gly. However among them, 223 
only genetic mutation in codon 94 were simultaneously associated with both low and 224 
high level of PZA resistance. In addition, 71 of 97 highly PZA resistant 225 
(MIC >500mg/L) isolates contained a substitution in one of the following regions: 226 
codon 51-76, codon 130-142 and codon 163-180, while 58 of 97 demonstrated an 227 
extremely high-level MIC (MIC>=1024mg/L). The pncA mutations also concentrated 228 
in two other regions (codon 94 to 97 and nucleotide -11 to codon 16) where the 229 
corresponding MICs demonstrated a relatively low level of PZA resistance (Figure 2). 230 
A comparison of MIC distribution (low-level and high-level) in the five regions 231 
mentioned above demonstrated statistical difference (p<0.001) (Table 2). 232 
 233 
The performance of pncA sequencing data to predict PZA resistance was evaluated and 234 
compared to the result obtained from the phenotypic MGIT 960 system (Table 3). 235 
Overall, 131 non-synonymous substitutions were found in PZA resistant isolates and 5 236 
 were found in PZA susceptible isolates. Molecular diagnosis currently identified 89.1% 237 
of PZA resistance. For MDR isolates and Beijing family isolates, the sensitivity 238 
reached 94.9% and 89.7%, respectively. Performance was comparable between isolates 239 
of the Beijing family (sensitivity: 89.7%, 95%CI: 83.46%-93.77%) and non-Beijing 240 
family (Sensitivity: 81.8%, 95%CI: 52.30%-94.86%), and between MDR-TB 241 
(Sensitivity: 94.9%, 95%CI: 83.11%-98.58%) and drug susceptible TB (Sensitivity: 242 
91.9%, 95%CI: 78.70%-97.20%). Furthermore，the sensitivity of pncA gene mutations 243 
to predict PZA resistance ranged from 81.8% to 94.7% in the studied sites, showing no 244 
statistically difference based on the 95%CI of the sensitivity and specificity. 245 
Socio-demographic and clinical characteristics associated with PZA resistance 246 
In primary univariate analysis (Table 4), age, prior treatment history and Beijing 247 
family genotype were found to be associated with PZA resistance; previous treatment 248 
history predicted a higher hazard of PZA mono-resistance. Age, prior treatment history, 249 
cavity and Beijing family genotype were positively associated with PZA resistance in 250 
MDR-TB patients.  251 
 252 
In a multivariable analysis, age, prior treatment history and Beijing family were 253 
retained in the model associated with PZA resistance, while in addition to the above 254 
variables, presence of cavities was also retained in the model of PZA-R/MDR-TB and 255 
age was removed from the model of PZA mono-R. Prior treatment history was a 256 
significant predictor of high risk for PZA resistance (p<0.001; OR: 3.30; 95%CI: 257 
2.131-5.101) both for PZA mono-resistance (p<0.005, OR: 2.86; 95%CI: 1.363-6.015) 258 
 and PZA-r/MDR-TB(p<0.001, OR: 6.47; 95%CI: 3.186-13.15). Age was found to be 259 
associated with PZA-R/MDR-TB (p=0.024; OR: 1.02; 95%CI: 1.003-1.042) and PZA 260 
resistance (p=0.012; OR: 1.01; 95%CI: 1.003-1.023), while Beijing family strain were 261 
associated with PZA resistance (p=0.019; OR: 2.25; 95%CI: 1.140-4.451). 262 
Additionally, MDR-TB patients with cavitation were more likely to be infected with 263 
PZA resistant strains (p=0.008; OR: 2.64; 95%CI: 1.296-5.391). 264 
 265 
DISCUSSION 266 
It has been widely accepted that PZA resistance could compromise anti-TB treatment, 267 
particularly MDR-TB treatment (15-17); however, there is little epidemiological data 268 
on PZA resistance, especially in high MDR-TB burden areas. In China, in contrast to 269 
earlier hospital-based studies or those conducted in a single region (18), the present 270 
study was multi-center, to better understand the epidemiological situation of PZA 271 
resistance across China. 272 
 273 
This is the first reported population-based study of PZA resistance among PTB cases in 274 
China. PZA susceptibility testing by BACTEC MGIT 960 revealed that 16.7% 275 
(147/878) of the studied patients were PZA resistant. Simultaneously, a higher level of 276 
PZA resistance (30.2% [39/129]) was found in the MDR-TB isolates, which is 277 
consistent with previously reported studies with PZA resistant rates ranging from 36% 278 
to 54% among MDR-TB patients (18-20). A significantly higher proportion of PZA 279 
resistance was observed in MDR cases compared to drug susceptible cases 280 
 (30.2%.vs.7.7%, p<0.001). Unfortunately, the overall PZA mono-resistance rate was 281 
7.7%, a rate higher than that reported in most areas with low TB incidence. This might 282 
have two explanations. Firstly, the PZA mono-resistance rate could be explained by the 283 
high proportion of previously treated patients included in the present study. Secondly, 284 
this could be due to an endemic spread of PZA mono-resistant strain, which has been 285 
observed elsewhere (21) or a combination of both. This suggests that PZA resistance 286 
has been established throughout China and that PZA susceptibility testing should be 287 
prioritized, especially among MDR-TB patients (even in areas with low prevalence of 288 
MDR-TB). 289 
 290 
For the 147 strains phenotypically resistant to PZA, mutations in the pncA gene were 291 
detected in 131 cases, indicating a sensitivity of 89.1%. In addition, as previous studies 292 
demonstrated, mutations were scattered throughout the pncA gene. Among the 731 293 
phenotypically PZA-susceptible isolates, we found 726 isolates with a wild type pncA, 294 
resulting in a specificity of 99.3%. Most importantly, the diagnostic performances of 295 
pncA mutations were similar irrespective of genotype (Beijing family vs. non-Beijing 296 
family), MDR and geographic area of origin. The most frequent alteration was 297 
observed in the putative promoter (nucleotide position -11), which might influence the 298 
initiation of protein synthesis and subsequent binding of the ribosome to the pncA 299 
mRNA (22). Additionally, the frequent mutation found at codon 57(7/130, 5.4%) were 300 
reported to be involved in the suppression of metal iron (Mg2+/Fe2+) binding, leading 301 
to a drastic decrease of PZase activity (23), while the mutation at codon 302 
 94(Phe94Leu/Cys/Ser) has been shown to be engaged in the hydrophobic core which 303 
would decrease the stability of the PZase. To our knowledge，4 SNPs (7 isolates) are 304 
reported here for the first time (Gly16Ser, Asp33Ala, Thr153Ile, Val163Gly), 305 
indicating the highly diverse patterns of pncA mutations. The isolates carrying these 306 
novel mutations (n=7) also had a high-level MIC and the role of these mutations needs 307 
to be studied further.  308 
 309 
Additionally, due to the clinical significance of MIC in TB treatment (24), we also 310 
related MIC levels to the pncA mutations, in an attempt to search for certain regions or 311 
substitutions that led to different levels of PZA resistance. In total, 97 of 133 PZA 312 
resistant isolates demonstrated a relatively high MIC (>500 mg/L), suggesting high 313 
level PZA resistance. Most interestingly, the majority of those cases were associated 314 
with mutations in three specific regions of the pncA gene (codon 51-76, codon 130-142 315 
and codon163-180). As previously reported (25), these three pncA regions related to 316 
high-level PZA resistance might be associated with the activity of PZase. As structural 317 
models of the PZase have revealed, these three specific regions were located in loop 4, 318 
loop 7 and loop 10, which all have been proven to be the part of PZase active site 319 
region (loop 7) and the metal coordination site (loop4) respectively (26). Our results 320 
were consistent with those studies and suggested that substitutions influencing the 321 
function of the PZase catalytic site could result in a high level of PZA resistance. 322 
Additionally, we also observed that for 7 codons, the same substitution led to different 323 
MIC values and this that other mechanisms apart from pncA mutation could also 324 
 influence the level of PZA resistance. Given the genetic profile of pncA in the PZA 325 
resistant isolates, a method based on these specific pncA regions might be of particular 326 
interest for a rapid molecular test of PZA resistance.  327 
 328 
Risk factors associated with PZA resistance among cases of Mtb are less well 329 
understood, especially in TB high-burden countries. In the present study, we did find 330 
that PZA mono-resistance was exclusively associated with previous treatment history. 331 
Additionally, given the important role of PZA in MDR-TB treatment, we also 332 
investigated the factors associated with PZA resistance among MDR-TB patients. In a 333 
multivariable analysis, factors significantly associated with MDR-PZA resistance 334 
included age and lung cavitation. Meanwhile despite the association between Beijing 335 
family and drug resistance has remained controversial with discrepant findings in 336 
China (27-29), in the present study, the association between Beijing family and PZA 337 
resistance was observed in other 1st line drug resistant strains rather than in isolates 338 
with PZA mono-resistance and MDR. This may rule out the possibility that the Beijing 339 
family in China has a propensity towards development of resistance to 340 
PZA. Alternatively, a secondary explanation could be that the risk of PZA resistance 341 
might be further increased within Beijing family strains due to other host 342 
characteristics relevant to other 1st line drug resistance (age and previous treatment 343 
history). According to these observations and also for the development of novel 344 
method for rapid identification of Beijing family strains (30), we would recommend 345 
testing for PZA susceptibility in previously treated patients and especially those 346 
 infected with strains of the Beijing family if possible. 347 
 348 
Our study was subject to several limitations. Since PZA susceptibility testing has not 349 
being routinely conducted in China, we decided to focus on four study sites with the 350 
ability to perform these tests. For the other areas that do not routinely test for PZA 351 
resistance, the prevalence may have been underestimated due to selection bias. 352 
Considering this limitation, we selected four areas with different geographic and 353 
socio-economic characteristics in China. We therefore think that the findings can give 354 
a reliable picture of the real situation. In addition, the phenotypic testing of PZA 355 
resistance was performed in the BACTEC MGIT 960 system which is the reference 356 
method recommended by WHO. The risk of false results using this methodology is 357 
however well known (31), but by randomly choosing 10% of the sputum culture 358 
samples and repeating the phenotypic DST with 100% consistency (compared to the 359 
previous testing), we estimate that our MGIT 960 method is reliable. 360 
 361 
Conclusion 362 
The significantly higher prevalence of PZA resistance in MDR-TB isolates (30%) 363 
highlights the need for PZA susceptibility testing in patients infected with MDR-TB 364 
and since PZA is an essential part of anti-MDR-TB treatment PZA resistance is 365 
undoubtedly an important public health issue which needs to be addressed. 366 
Additionally，the reliable performance of pncA mutations in detecting PZA resistance 367 
 as well as the association between specific regions of pncA and high-level PZA 368 
resistance, show the value of a rapid molecular test for PZA resistance. 369 
 370 
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 Table1. Demographic and clinical characteristics of patients and drug-resistant patterns at diagnosis in the four studied sites 486 
  GY DQ GJ RO Total     
Variables (n=254) (n=216) (n=237) (n=171) (n=878) χ² p 
Male(Gender) 184(72.4) 152(70.4) 157(66.2) 115(67.3) 608(69.2) 2.668 0.446 
Age(Mean±SD) 45.3±19.5 48.2±18.0 47.5±19.5 49.1±19.9 47.3±19.2 1.626a 0.182 
Prior treatment 
history 
56(22.0) 41(19.0) 52(21.9) 36(21.1) 185(21.1) 0.820  0.845 
Sputum Smear 
positive 
159(62.6) 140(64.8) 143(60.3) 91(53.2) 533(60.7) 5.945 0.114 
Cavity 70(27.6) 47(21.8) 62(26.2) 48(28.1) 227(25.9) 2.724 0.436 
1st-line Drug susceptibilities 
DS 116(45.7) 134(62.0) 128(54.0) 100(58.5) 478(54.4) 22.468 0.001b 
MDR 34(13.4) 25(11.6) 40(16.9) 30(17.5) 129(14.7) 
 ODR 104(40.9) 57(26.4) 69(29.1) 41(24.0) 271(30.9) 
PZA susceptibilities 
PZA resistance 44(17.3) 37(17.1) 38(16.0) 28(16.4) 147(16.7) 0.187 0.980 
PZA mono-R 12(4.7) 13(6.0) 6(2.5) 6(3.5) 37(4.2) 3.779 0.286 
PZA-R/MDR 8(3.1) 9(4.2) 11(4.6) 11(6.4) 39(4.4) 2.657 0.448 
Note: DS: Drug susceptible; MDR: Multidrug-resistant; ODR: Other drug resistant: PZA: pyrazinamide 487 
a F value for ANOVA test 488 
b p<0.05  489 
  490 
Figure 1.Number of mutations at each codon in the pncA gene among different resistance patterns  491 
  492 
 493 
Figure 2.The frequency and MICs of PZA among the isolates with mutations in pncA gene. The MIC is presented for each isolate and the 494 
symbols above the dotted line indicate high level PZA resistance (MIC>500mg/L). 495 
  496 
 Table2. Regions of pncA correlated with low or high-level PZA resistance 497 
  Total 
low-level PZA 
resistance(MIC≤500mg/L) 
high-level PZA 
resistance(MIC>500mg/L) 
p a 
Codon 51-76 34 5(14.7) 29(85.3) 
Codon 130-142 28 0(0.0) 28(100.0) 
Codon 163-180 14 0(0.0) 14(100.0) <0.001 
Codon 94-97 16 6(37.5) 10(62.5) 
Nucleotide -11 to 
codon 16 
29 
21(72.4) 8(27.6)   
Note: PZA: pyrazinamide 498 
a Calculated by Fisher exact test499 
 Table 3.Comparison of non-synonymous pncA mutations with PZA resistance results based on BATECT MGIT 960 500 
PZA susceptibility 
No. of isolates with: 
Sensitivity % (95%CI) Specificity %(95%CI) ROC-AUC(95%CI)pncA nonsynonymous 
mutations 
 
pncA wide type or synonymous 
mutations 
Overall, n=878 
Resistant 131 16 89.1(83.05, 93.19) 99.3(98.41,99.71) 0.94(0.925,0.957) 
Susceptible 5 726 
 
MDR-TB, n=129 
 
Resistant 37 2 94.9(83.11,98.58) 96.7(90.65,98.86) 0.96(0.907,0.985) 
Susceptible 3 87 
 
ODR-TB, n=271 
 
Resistant 60 11 84.5(74.35, 91.12) 99.0(96.43, 99.73) 0.92(0.878,0.947) 
Susceptible 2 198 
 
 DS, n=478 
 
Resistant 34 3 91.9(78.70, 97.20) 100.0(99.14, 100.00) 0.96(0.938,0.975) 
Susceptible 0 441 
 
Beijing strain, n=739 
 
Resistant 122 14 89.7(83.46,93.77) 99.2(98.07%,99.65) 0.94(0.925,0.960) 
Susceptible 5 598 
 
Non-Beijing strain, n=139 
 
Resistant 9 2 81.8(52.30, 94.86) 100.0(97.09, 100.00) 0.91(0.849,0.951) 
Susceptible 0 128 
 
GY, n=254 
      
Resistant 36 8 81.8(68.04,90.49) 99.0(96.59,99.74) 0.90(0.861,0.938) 
Susceptible 2 208 
 
DQ, n=216 
      
 Resistant 33 4 89.2(75.29,95.71) 98.3(95.19,99.43) 0.94(0.897,0.966) 
Susceptible 3 176 
 
GJ, n=237 
    
Resistant 36 2 94.7(82.71,98.54) 100.0(98.11,100.00) 0.97(0.944,0.990) 
Susceptible 0 199 
 
RO, n=171 
    
Resistant 26 2 92.9(77.35,98.02) 100.0(97.38,100.00) 0.96(0.924,0.987) 
Susceptible 0  143       
Note: DS: drug susceptible; MDR: multidrug-resistant; ODR: other drug resistant: PZA: pyrazinamide; ROC-AUC: The area under the receiver 501 
operating characteristic curve.  502 
 Table4. Socio-demographic and clinical characteristics associated with PZA resistance 503 
Risk factors 
PZA 
Mono-Ra 
N=37 
 
PZA-R/MDR
b N=39 
 
PZA-
R 
N=147 
 
DrugSc 
N=441 
 
PZA mono-R VS 
DrugS 
 
PZA-R/MDR VS 
DrugS 
 PZA-R VS DrugS 
n(%)  n(%)  n(%)  n(%)  pd OR(95%CI)d  pd OR(95%CI)d  pd OR(95%CI)d 
Gender(Male
) 
30 
(81.1)  
26 
(66.7)  
106 
(72.1)  
301 
(68.3)  
0.110 
1.99 
(0.855-4.649)  
0.838 
0.93 
(0.464-1.864)  
0.381 
1.20 
(0.796-1.816
) 
Age 
51.1 
±21.3  
54.4 
±20.3  
54.4 
±20.3  
46.8 
±18.8  
0.189 
1.01 
(0.994-1.030)  
0.018e 
1.02 
(1.004-1.039)  
0.003e 
1.02 
(1.005-1.025
) 
Prior 12 
 
20 
 
53 
 
62 
 
0.004e 2.93 
 
<0.001e 6.44 
 
<0.001 3.45 
 treatment 
history 
(32.4) (51.3) (36.1) (14.1) (1.402-6.143) (3.250-12.74) e (2.241-5.302
) 
Sputum 
smear 
Positive 
23 
(62.2)  
25 
(64.1)  
91 
(61.9)  
260 
(59.0)  
0.703 
1.14 
(0.573-2.282)  
0.531 
1.24 
(0.629-2.457)  
0.528 
1.13 
(0.771-1.659
) 
Cavity 
10 
(27.0)  
18 
(46.2)  
38 
(25.9)  
112 
(25.4)  
0.827 
1.09 
(0.511-2.318)  
0.007e 
2.52 
(1.295-4.896)  
0.913 
1.02 
(0.668-1.570
) 
Beijing F 
35 
(94.6) 
 
38 
(97.4) 
 
136 
(92.5) 
 
369 
(83.7) 
 0.096 
3.42 
(0.803-13.52) 
 0.050e 
7.42 
(1.002-44.87) 
 0.009e 
2.41 
(1.242-4.287
) 
Note: DS: drug susceptible; MDR: multidrug-resistant; ODR: other drug resistant: PZA: pyrazinamide; 504 
 a PZA mono-R: isolates resistant to PZA but susceptible to isoniazid, rifampicin, ethambutol and streptomycin;  505 
b PZA-R/MDR: isolates resistant to PZA as well as at least resistant to isoniazid and rifampicin;  506 
c DrugS: isolates susceptible to all the 5 tested drugs (isoniazid, rifampicin, ethambutol, streptomycin and pyrazinamide ); 507 
d p and OR(95%CI) derived from the Binary Logistic Regression model; 508 
e p<0.05.  509 
 Table 5. Multivariate analysis of demographic and clinical characteristics associated with PZA resistance 510 
  β p OR(95%CI)a 
PZA mono-R vs Drug S 
Prior Treatment History 1.052 0.005b 2.86(1.363-6.015) 
Beijing Family 1.186 0.109 3.28(0.766-14.00) 
PZA-R/MDR vs Drug S 
Age 0.022 0.024b 1.02(1.003-1.042) 
Prior Treatment History 1.867 <0.001b 6.47(3.186-13.15) 
Cavity 0.972 0.008b 2.64(1.296-5.391) 
Beijing Family 1.849 0.074 6.35(0.838-48.14) 
PZA-R vs Drug S 
Age 0.013 0.012b 1.01(1.003-1.023) 
Prior Treatment History 1.193 <0.001b 3.30(2.131-5.101) 
 Beijing Family 0.812 0.019b 2.25(1.140-4.451) 
Note: DS: drug susceptible; MDR: multidrug-resistant; ODR: other drug resistant: PZA: pyrazinamide. 511 
a OR and 95%CI was calculated in the Binary Logistic Regression model by backward selection 512 
b p<0.05 513 
